Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis

Endocrinology

Volumn 152, Issue 12, 2011, Pages 4504-4513

  Ichikawa, Shoji ^a   Austin, Anthony M ^a   Gray, Amie K ^a   Allen, Matthew R ^a   Econs, Michael J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; OSTEOCALCIN; PHOSPHATE; PHOSPHORUS;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CORTICAL BONE; CREATININE BLOOD LEVEL; DIET RESTRICTION; FEMALE; FERTILITY; HYPERPHOSPHATEMIA; LITTER SIZE; MALE; MALE INFERTILITY; MOUSE; NONHUMAN; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PRIORITY JOURNAL; SEX DIFFERENCE; TRABECULAR BONE; TUMOR CALCINOSIS; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BONE AND BONES; BONE DENSITY; CALCINOSIS; DIET; DISEASE MODELS, ANIMAL; INFERTILITY, MALE; MALE; MICE; MICE, KNOCKOUT; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEOPLASMS; PHOSPHATES;

EID: 82355188241     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1137     Document Type: Article

References (42)

1. Carmichael KD, Bynum JA, Evans EB 2009 Familial tumoral calcinosis: a forty-year follow-up on one family. J Bone Joint Surg Am 91:664-671
2. Ichikawa S, Baujat G, Seyahi A, Garoufali AG, Imel EA, Padgett LR, Austin AM, Sorenson AH, Pejin Z, Topouchian V, Quartier P, Cormier-Daire V, Dechaux M, Malandrinou FCh, Singhellakis PN, Le Merrer M, EconsMJ2010 Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am J Med Genet A 152A:896-903
3. McPhaul Jr JJ, Engel FL 1961 Heterotopic calcification, hyperphosphatemia and angioid streaks of the retina. Am J Med 31:488-492
4. Ghanchi F, Ramsay A, Coupland S, Barr D, Lee WR 1996 Ocular tumoral calcinosis. A clinicopathologic study. Arch Ophthalmol 114:341-345
5. Lyles KW, Burkes EJ, Ellis GJ, Lucas KJ, Dolan EA, Drezner MK 1985 Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity. J Clin Endocrinol Metab 60:1093-1096 (Pubitemid 15064764)
6. Clarke E, Swischuk LE, Hayden Jr CK 1984 Tumoral calcinosis, diaphysitis, and hyperphosphatemia. Radiology 151:643-646 (Pubitemid 14112760)
7. Narchi H 1997 Hyperostosis with hyperphosphatemia: evidence of familial occurrence and association with tumoral calcinosis. Pediatrics 99:745-748 (Pubitemid 27193781)
8. Wilson MP, Lindsley CB, Warady BA, Johnson JA 1989 Hyperphosphatemia associated with cortical hyperostosis and tumoral calcinosis. J Pediatr 114:1010-1013 (Pubitemid 19151764)
9. Dumitrescu CE, Kelly MH, Khosravi A, Hart TC, Brahim J, White KE, Farrow EG, Nathan MH, Murphey MD, Collins MT 2009 A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features. Osteoporos Int 20:1273-1278
10. Joseph L, Hing SN, Presneau N, O'Donnell P, Diss T, Idowu BD, Joseph S, Flanagan AM, Delaney D 2010 Familial tumoral calcinosis and hyperostosis- hyperphosphataemia syndrome are different manifestations of the same disease: novel missense mutations in GALNT3. Skeletal Radiol 39:63-68
11. Frishberg Y, Topaz O, Bergman R, Behar D, Fisher D, Gordon D, Richard G, Sprecher E 2005 Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J Mol Med 83:33-38 (Pubitemid 40169494)
12. Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T 2005 A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90:5523-5527 (Pubitemid 41415453)
13. Benet-Pagès A, Orlik P, Strom TM, Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385-390 (Pubitemid 40220655)
14. Chefetz I, Heller R, Galli-Tsinopoulou A, Richard G, Wollnik B, Indelman M, Koerber F, Topaz O, Bergman R, Sprecher E, Schoenau E 2005 A novel homozygous missense mutation in FGF23 causes familial tumoral calcinosis associated with disseminated visceral calcification. Hum Genet 118:261-266 (Pubitemid 41672088)
15. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE 2005 A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424-2427 (Pubitemid 40586293)
16. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505 (Pubitemid 32488266)
17. +-dependent phosphate co-transport activity and 1α,25- dihydroxyvitamin D3 production. J Biol Chem 278: 2206-2211
18. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179-3182 (Pubitemid 34809892)
19. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ 2007 A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117:2684-2691 (Pubitemid 47494368)
20. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M 2006 Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120-6123 (Pubitemid 43847540)
21. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T 2006 Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774 (Pubitemid 44949607)
22. Ichikawa S, Lyles KW, Econs MJ 2005 A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab 90:2420-2423 (Pubitemid 40590063)
23. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E 2004 Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579-581 (Pubitemid 38715983)
24. Frishberg Y, Ito N, Rinat C, Yamazaki Y, Feinstein S, Urakawa I, Navon-Elkan P, Becker-Cohen R, Yamashita T, Araya K, Igarashi T, Fujita T, Fukumoto S 2007 Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 22:235-242 (Pubitemid 46167794)
25. Kato K, Jeanneau C, Tarp MA, Benet-Pagès A, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Clausen H 2006 Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281:18370-18377 (Pubitemid 44035494)
26. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435 (Pubitemid 38787398)
27. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Jüppner H, Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the α1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-3094 (Pubitemid 38829975)
28. Bai X, Miao D, Li J, Goltzman D, Karaplis AC 2004 Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269-5279 (Pubitemid 39551149)
29. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T 2005 Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289:F1088-F1095 (Pubitemid 41447065)
30. Ichikawa S, Guigonis V, Imel EA, Courouble M, Heissat S, Henley JD, Sorenson AH, Petit B, Lienhardt A, Econs MJ 2007 Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 92:1943-1947 (Pubitemid 46997214)
31. Ichikawa S, Imel EA, Sorenson AH, Severe R, Knudson P, Harris GJ, Shaker JL, Econs MJ 2006 Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J Clin Endocrinol Metab 91: 4472-4475 (Pubitemid 44833425)
32. Ichikawa S, Sorenson AH, Austin AM, Mackenzie DS, Fritz TA, Moh A, Hui SL, Econs MJ 2009 Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology 150:2543-2550
33. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960 (Pubitemid 35316332)
34. Garringer HJ, Fisher C, Larsson TE, Davis SI, Koller DL, Cullen MJ, Draman MS, Conlon N, Jain A, Fedarko NS, Dasgupta B, White KE 2006 The role of mutant UDP-N-acetyl-α-D-galactosamine-polypeptideN- acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 91:4037-4042 (Pubitemid 44536883)
35. Garringer HJ, Mortazavi SMJ, Esteghamat F, Malekpour M, Boztepe H, Tanakol R, Davis SI, White KE 2007 Two novel GALNT3 mutations in familial tumoral calcinosis. Am J Med Genet A 143: 2390-2396 (Pubitemid 47511930)
36. Kawaguchi H, Manabe N, Miyaura C, Chikuda H, Nakamura K, Kuro-o M 1999 Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest 104:229-237
37. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI 1997 Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51 (Pubitemid 27494749)
38. Yamashita T, Nabeshima Y, NodaM2000 High-resolution microcomputed tomography analyses of the abnormal trabecular bone structures in klotho gene mutant mice. J Endocrinol 164:239-245 (Pubitemid 30114671)
39. Yamashita T, Nifuji A, Furuya K, Nabeshima Y, Noda M 1998 Elongation of the epiphyseal trabecular bone in transgenic mice carrying a klotho gene locus mutation that leads to a syndrome resembling aging. J Endocrinol 159:1-8 (Pubitemid 28459260)
40. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568 (Pubitemid 38542505)
41. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Jüppner H, Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-432 (Pubitemid 39576657)
42. Ohnishi M, Razzaque MS 2010 Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 24: 3562-3571